

CHEMICAL MANUFACTURERS ASSOCIATION
Vinyl Chloride Health Committee
Tentative Meeting Agenda

DATE: April 23, 1997.
TIME: 9:30 a.m. - 3:00 p.m. DST
PLACE: Georgetown Conference Room

- 1.0 Approval of the February 18, 1997 Record of Conference Call
- 2.0 Update on the Developmental, Reproductive and Mechanistic Research Studies *See comments on other sheet,*
- 2.1 Huntingdon Life Sciences Developmental and Reproductive Studies
- 2.2 University of North Carolina - J. Swenberg Satellite Study
- 2.3 Status of Progress Reports to ATSDR *See other sheet for comments*
- 3.0 Update on the International Life Sciences Institute Genotoxicity Project *• We contributed \$10,000 to ILSI for this project.*
- 4.0 Update on EPA's IRIS Pilot Project *See comments on other sheet*
- 5.0 Update on the University of Louisville Brain Cancer Study *See other sheet for comments*
- 6.0 Update on the Vinyl Chloride Cohort Study with Applied Epidemiology Inc. *• End of May, more data will be submitted to ATSDR with accompanying subsequent submission*
- 7.0 Update on ATSDR Activities *• Substantiated progress in cleaning solvent data base*
- 7.1 Status of Comments on the Toxicological Profile for Vinyl Chloride
- 7.2 Status of Activity on the Minimal Risk Level for Vinyl Chloride
- 7.3 Status of the Medical Management Practices Guideline *• Essentially complete w/ respect to funding and funding*
- 8.0 Financial Update *• Comments on 6/10/97*
- 9.0 Schedule Next Meeting or Conference Call *• Data analysis including 2 to 4 more*
- Subject to Approval

Subject to Approval

Wendy K. Sherman
Manager
Vinyl Chloride Health Committee

NOTE: Below items do not increase overall budget.

4: Approved H-CM additional for Huntington Life Science, Inc.
on 1/30. H-CM for Secondary studies.

NOTE: Re APME Registry of ASH:
Panel will comment on behalf of industry —
BFG 00021
T. N. S. will draft comments & share with
Acad. & others for final review.

ANTITRUST CHECKLIST FOR CMA MEETINGS

This antitrust checklist is for use by CMA staff and member representatives in the conduct of CMA-sponsored meetings. *Prohibited discussion topics apply equally to social gatherings incidental to CMA-sponsored meetings.* The Checklist is not exhaustive and does not address antitrust issues relating to activities other than CMA meetings. Participants in CMA meetings also should be thoroughly familiar with: (1) "Antitrust Guide for CMA Committee Members;" and, (2) "General Principles Applicable to the Structure and Operations of Committees." Both of these documents may be found in the CMA Directory.

DO

Ensure strict performance in areas of:

OVERSIGHT/SUPERVISION:

- Have a CMA staff representative at each CMA-sponsored meeting (unless an exception has been authorized by the appropriate CMA vice president);
- consult with an attorney of the CMA Office of General Counsel on all antitrust questions relating to CMA-sponsored meetings;
- limit meeting discussions to agenda topics (unless additional topics have been approved by the appropriate CMA staff representative); and
- provide each member company representative and CMA staff representative attending a CMA-sponsored meeting with a copy of this checklist, and have a copy available for reference at all CMA-sponsored meetings.

RECORDKEEPING:

- Have an agenda and minutes which accurately reflect the matters which occur;
- provide agendas and minutes to the CMA Office of General Counsel for review and approval in advance of distribution; and,
- fully describe the purposes and authorities of all task groups, work groups, ad hoc or other standing committee subgroups in the minutes of the appropriate parent committee.

VIGILANCE:

- Protest against any discussion or meeting activities which appear to violate this checklist; dissociate yourself from any such discussion or activities and leave any meeting in which they continue.

DON'T

Do not, in fact or appearance, discuss or exchange information on:

PRICES, INCLUDING:

- Individual company prices, price changes, price differentials, markups, discounts, allowances, credit terms, etc.;
- individual company data on costs, production, capacity, inventories, sales, etc.; and,
- industry pricing policies, price levels, price changes, differentials, etc.

PRODUCTION, INCLUDING:

- Plans of individual companies concerning the design, production, distribution or marketing of particular products, including proposed territories or customers; and,
- changes in industry production, capacity or inventories.

TRANSPORTATION RATES:

- Rates or rate policies for individual shipments, including basing point systems, zone prices, freight equalization, etc.

MARKET PROCEDURES, INCLUDING:

- Company bids on contracts for particular products; company procedures for responding to bid invitations; and,
- matters relating to actual or potential individual suppliers or customers that might have the effect of excluding them from any market or influencing the business conduct of firms toward them.

CONSENT DECREE SUBSTANCE:

- Any matter relating to trisodium phosphate (a restriction required by a 1962 consent decree to which CMA is a party).

C 4/23/97 W
CMA VC. Power
Health Comm Mtg.

CHEMICAL MANUFACTURERS ASSOCIATION

Vinyl Chloride Health Committee
Meeting With the University of Louisville
Tentative Agenda

DATE: April 18, 1997
TIME: 8:30 a.m. - 2:30 p.m.
PLACE: Health Sciences Center
University of Louisville
Louisville, KY

- Ralph Shuman very strong
influence on the mtg. & will be
involved in further study conduct.

- 8:30-9:00 1.0 Review Agenda Items and Objectives
- 9:00-9:30 2.0 Status of Work in Progress at the University of Louisville
- 9:30-9:45 3.0 Update on Cohort Mortality Study at the Applied Epidemiology, Inc.
- 9:45-10:15 4.0 Discussion of Greenberg/Tamburro Methodology for Analysis of BF Goodrich Cohort Data, Including Statistical Powers *will be used, but —*
- 10:45-11:00 Break *incorporate features of*
- 11:00-12:00 5.0 Discussion of Classical Case Control Analysis of BF Goodrich Cohort Data
- 12:00-12:30 6.0 Consensus on Methods of Analysis and Publication of Final Study Results
- 12:30-1:30 Lunch
- 1:30-2:30 7.0 Development of Final Protocol
 - 7.1 Review GEP's to Assure that the Final Protocol Meets All Applicable Guidelines
 - 7.2 Develop a Strategy for Addressing Peer Reviewers Comments in the Protocol
 - 7.3 Establish a Time Line for Preparation, Reviews, and Approval of Final Protocol
 - 7.4 Discuss Peer Reviewers' Sign-off of the Final Protocol

* Focus is to increase the analytical/statistical power
of Tamburro's study. Should have positive impact on
credibility w/ peers & public audiences.

Item 50 > Tamlumbe Study:

- Workshop in Oct to 04/16/93.

- Using Mantel study without records to be a case
study. (Concurrently 194 children
- present in a brain tumor cases - including any
adjustment as 194 children are cleared.
19% of 10 children

8 - See comments on Agenda from 07/15/93 with all of h.

Item 50 > Harting's life Sciences (Purdue review 02/10)

- Initial character studies are well underway

Soft tissue problem results indicate no problems with
developmental toxicity. Skeletal, etc remain to be evaluated.

Soft tissue problem results appear normal.

Soft tissue problem results appear normal. Soft tissue problem results appear normal.
Soft tissue problem results appear normal. Soft tissue problem results appear normal.

Item 50 > SWENBERG BATTERITE STUDY > Awaiting formal protocol, and waiting asking for H

Item 50 > II - Pilot Project - Draft of peer review in 05/93

More exposure closely for approval by 10 p.m. in
comments period.

CHEMICAL MANUFACTURERS ASSOCIATION
Vinyl Chloride Health Committee
Tentative Meeting Agenda

DATE: April 23, 1997
TIME: 9:30 a.m. - 3:00 p.m. DST
PLACE: Georgetown Conference Room

- 1.0 Approval of the February 18, 1997 Record of Conference Call
- 2.0 Update on the Developmental, Reproductive and Mechanistic Research Studies
 - 2.1 Huntingdon Life Sciences Developmental and Reproductive Studies
 - 2.2 University of North Carolina - J. Swenberg Satellite Study
 - 2.3 Status of Progress Reports to ATSDR
- 3.0 Update on the International Life Sciences Institute Genotoxicity Project
- 4.0 Update on EPA's IRIS Pilot Project
- 5.0 Update on the University of Louisville Brain Cancer Study
- 6.0 Update on the Vinyl Chloride Cohort Study with Applied Epidemiology Inc.
- 7.0 Update on ATSDR Activities
 - 7.1 Status of Comments on the *Toxicological Profile for Vinyl Chloride*
 - 7.2 Status of Activity on the Minimal Risk Level for Vinyl Chloride
 - 7.3 Status of the Medical Management Practices Guideline
- 8.0 Financial Update
- 9.0 Schedule Next Meeting or Conference Call

Subject to Approval

Wendy K. Sherman
Manager
Vinyl Chloride Health Committee